Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.

<h4>Background</h4>Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this ga...

Full description

Bibliographic Details
Main Authors: Milika Rinamalo, Lorenzo Pezzoli, Mike Kama, Eric Rafai, Ilisapeci Kubuabola, Mosese Salusalu, Sung Hye Kim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0238622
id doaj-7115d1e718c7456684a03a2181ed3700
record_format Article
spelling doaj-7115d1e718c7456684a03a2181ed37002021-03-04T11:12:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01159e023862210.1371/journal.pone.0238622Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.Milika RinamaloLorenzo PezzoliMike KamaEric RafaiIlisapeci KubuabolaMosese SalusaluSung Hye Kim<h4>Background</h4>Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot quality assurance sampling (LQAS) following the 10th annual LF-MDA round in Fiji to explore whether there was any area in which target coverage was not reached. We also assessed the level of drug compliance and satisfaction with the LF-MDA implementation strategy.<h4>Methodology/principal findings</h4>We conducted a cross-sectional household survey in 3 divisions of Fiji. For LQAS, we defined 19 lots in 7 medical areas of the Suva sub-division and another 12 sub-divisions in the Central, Northern, and Eastern Divisions. A sample of 16 randomly selected household members was taken un each lot. We defined our decision rule as follows: if more than 1 person in a given lot did not swallow the medication, coverage was considered inadequate, i.e. less than 80%. Of the 7 lots in Suva sub-division and 12 lots in the 3 divisions, five and two lots, respectively, were identified as having inadequate coverage. The overall program coverage estimated from 304 samples was 92%, which was higher than the reported administrative coverage of 82%. About 98% of interviewees were offered the medication and 96% swallowed it. Non-participation arose from insufficient information on how to obtain the drugs. At least 92% were satisfied with the LF-MDA implementation strategy.<h4>Conclusions</h4>Areas of low program coverage with results discordant with the reported administrative coverage existed in both urban and rural settings. Drug compliance and satisfaction were high, even after repeated rounds. We recommend increasing efforts to deliver the service in those areas with inadequate program coverage, as well as conducting timely coverage assessment through LQAS for corrective action.https://doi.org/10.1371/journal.pone.0238622
collection DOAJ
language English
format Article
sources DOAJ
author Milika Rinamalo
Lorenzo Pezzoli
Mike Kama
Eric Rafai
Ilisapeci Kubuabola
Mosese Salusalu
Sung Hye Kim
spellingShingle Milika Rinamalo
Lorenzo Pezzoli
Mike Kama
Eric Rafai
Ilisapeci Kubuabola
Mosese Salusalu
Sung Hye Kim
Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.
PLoS ONE
author_facet Milika Rinamalo
Lorenzo Pezzoli
Mike Kama
Eric Rafai
Ilisapeci Kubuabola
Mosese Salusalu
Sung Hye Kim
author_sort Milika Rinamalo
title Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.
title_short Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.
title_full Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.
title_fullStr Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.
title_full_unstemmed Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.
title_sort lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in fiji: a methodological approach.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2020-01-01
description <h4>Background</h4>Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot quality assurance sampling (LQAS) following the 10th annual LF-MDA round in Fiji to explore whether there was any area in which target coverage was not reached. We also assessed the level of drug compliance and satisfaction with the LF-MDA implementation strategy.<h4>Methodology/principal findings</h4>We conducted a cross-sectional household survey in 3 divisions of Fiji. For LQAS, we defined 19 lots in 7 medical areas of the Suva sub-division and another 12 sub-divisions in the Central, Northern, and Eastern Divisions. A sample of 16 randomly selected household members was taken un each lot. We defined our decision rule as follows: if more than 1 person in a given lot did not swallow the medication, coverage was considered inadequate, i.e. less than 80%. Of the 7 lots in Suva sub-division and 12 lots in the 3 divisions, five and two lots, respectively, were identified as having inadequate coverage. The overall program coverage estimated from 304 samples was 92%, which was higher than the reported administrative coverage of 82%. About 98% of interviewees were offered the medication and 96% swallowed it. Non-participation arose from insufficient information on how to obtain the drugs. At least 92% were satisfied with the LF-MDA implementation strategy.<h4>Conclusions</h4>Areas of low program coverage with results discordant with the reported administrative coverage existed in both urban and rural settings. Drug compliance and satisfaction were high, even after repeated rounds. We recommend increasing efforts to deliver the service in those areas with inadequate program coverage, as well as conducting timely coverage assessment through LQAS for corrective action.
url https://doi.org/10.1371/journal.pone.0238622
work_keys_str_mv AT milikarinamalo lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT lorenzopezzoli lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT mikekama lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT ericrafai lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT ilisapecikubuabola lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT mosesesalusalu lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
AT sunghyekim lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach
_version_ 1714804519358955520